The morbidity and cost implications of hemodialysis clinical performance measures

Hemodialysis International

Volumn 9, Issue 4, 2005, Pages 349-361

  O'Connor, Andrew S ^a,b   Wish, Jay B ^a,c   Sehgal, Ashwini R ^a,b  

^a CASE WESTERN RESERVE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b METROHEALTH MEDICAL CENTER   (United States)

^c UNIVERSITY HOSPITALS OF CLEVELAND   (United States)

Author keywords

Dialysis outcomes; Hemodialysis; Quality improvement; Quality of care

Indexed keywords

ALBUMIN; HEMOGLOBIN;

ADULT; ARTERIOVENOUS FISTULA; ARTICLE; CONFIDENCE INTERVAL; CONTROLLED STUDY; DATA ANALYSIS; DEMOGRAPHY; FEMALE; HEALTH CARE COST; HEALTH CARE QUALITY; HEMODIALYSIS; HEMODIALYSIS PATIENT; HOSPITAL PATIENT; HOSPITAL UTILIZATION; HOSPITALIZATION; HUMAN; LENGTH OF STAY; MAJOR CLINICAL STUDY; MALE; MEDICARE; MORBIDITY; NUTRITION; PATIENT MONITORING; REIMBURSEMENT; SAMPLE SIZE; VASCULAR ACCESS;

COSTS AND COST ANALYSIS; HOSPITALIZATION; HUMANS; INPATIENTS; MEDICARE; MORBIDITY; QUALITY OF HEALTH CARE; RENAL DIALYSIS; UNITED STATES;

EID: 27744522189     PISSN: 14927535     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1542-4758.2005.01153.x     Document Type: Article

References (54)

1. Blagg CR, Liedtke RJ, Batjer JD, Racoosin B, Sawyer TK, Wick MJ, Lawson L, Wilkens K. Serum albumin concentration-related health care financing administration quality assurance criterion is method-dependent: Revision is necessary. Am J Kidney Dis. 1993; 21:138-144.
2. Evans RW, Rader B, Manninen DL. The quality of life of hemodialysis recipients treated with recombinant human erythropoietin. Cooperative multicenter EPO clinical trial group. JAMA. 1990; 263:825-830.
3. Owen WF Jr, Lew NL, Liu Y, Lowrie EG, Lazarus JM. The urea reduction ratio and serum albumin concentration as predictors of mortality in patients undergoing hemodialysis. N Engl J Med. 1993; 329:1001-1006.
4. Sehgal AR, Dor A, Tsai AC. Morbidity and cost implications of inadequate hemodialysis. Am J Kidney Dis. 2001; 37:1223-1231.
5. McClellan WM, Soucie JM, Krisher J, Caruana R, Haley W, Farmer C. Improving the care of patients treated with hemodialysis: A report from the health care financing administration's ESRD core indicators project. Am J Kidney Dis. 1998; 31:584-592.
6. McClellan WM, Frankenfield DL, Frederick PR, Helgerson SD, Wish JB, Sugarman JR. Improving the care of ESRD patients: A success story. Health Care Finance Rev. 2003; 24:89-100.
7. McClellan WM, Frankenfield DL, Frederick PR, Flanders WD, Alfaro-Correa A, Rocco M, Helgerson SD. Can dialysis therapy be improved? A report from the ESRD core indicators project. Am J Kidney Dis. 1999; 34:1075-1082.
8. Lowrie EG, Teng M, Lacson E, Lew N, Lazarus JM, Owen WF. Association between prevalent care process measures and facility-specific mortality rates. Kidney Int. 2001; 60:1917-1929.
9. Frankenfield DL, Rocco MV, Frederick PR, Pugh J, McClellan WM, Owen WF Jr. Racial/ethnic analysis of selected intermediate outcomes for hemodialysis patients: Results from the 1997 ESRD core indicators project. Am J Kidney Dis. 1999; 34:721-730.
10. O'Connor AS, Leon JB, Sehgal AR. The relative predictive ability of four different measures of hemodialysis dose. Am J Kidney Dis. 2002; 40:1289-1294.
11. Kloppenburg WD, Stegeman CA, Hooyschuur M, vander Ven DV, de Jong PE, Huisman RM. Assessing dialysis adequacy and dietary intake in the individual hemodialysis patient. Kidney Int. 1999; 55:1961-1969.
12. Collins A, Li S, Ebben J, Ma J, Manning W. Hematocrit levels and associated medicare expenditures. Am J Kidney Dis. 2000; 36:282-293.
13. Glynn RJ, Stukel TA, Sharp SM, Bubolz TA, Freeman JL, Fisher ES. Estimating the variance of standardized rates of recurrent events, with application to hospitalizations among the elderly in New England. Am J Epidemiol. 1993; 137:776-786.
14. Fink JC, Gardner JF, Armistead NC, Turner MS, Light PD. Within-center correlation in dialysis adequacy. J Clin Epidemiol. 2000; 53:79-85.
15. Long JS. Limited outcomes: The tobit model. In: Long JS ed. Regression Models for Categorical and Limited Dependent Variables, chapter 7. Thousand Oaks, CA: Sage Publications; 1997:187-216.
16. Feldman HI, Held PJ, Hutchinson JT, Stoiber E, Hartigan MF, Berlin JA. Hemodialysis vascular access morbidity in the United States. Kidney Int. 1993; 43:1091-1096.
17. Sehgal AR, Silver MR, Covinsky KE, Coffin R, Cain JA. Use of standardized ratios to examine variability in hemodialysis vascular access across facilities. Medical Review Board of The Renal Network, Inc. Am J Kidney Dis. 2000; 35:275-281.
18. Strawderman RL, Levine G, Hirth RA, Port FK, Held PJ. Using USRDS generated hospitalization tables to compare local dialysis patient hospitalization rates to national rates. Kidney Int. 1996; 50:571-578.
19. Mix TC, Peter W, Ebben J, Xue J, Pereira B, Kausz A, Collins A. Hospitalization during advancing chronic kidney disease. Am J Kidney Dis. 2003; 42:972-981.
20. Powe NR, Griffiths RI, Watson AJ, Anderson GF, de Lissovoy G, Greer JW, Herbert RJ, Milam RA, Whelton PK. Effect of recombinant erythropoietin on hospital admissions, readmissions, length of stay, and costs of dialysis patients. J Am Soc Nephrol. 1994; 4:1455-1465.
21. Rocco MV, Soucie JM, Reboussin DM, McClellan WM. Risk factors for hospital utilization in chronic dialysis patients. Southeastern kidney council (network 6). J Am Soc Nephrol. 1996; 7:889-896.
22. Eknoyan G, Beck GJ, Cheung AK, Daugirdas JT, Greene T, Kusek JW, Allon M, Bailey J, Delmez JA, Depner TA, Dwyer JT, Levey AS, Levin NW, Milford E, Ornt DB, Rocco MV, Schulman G, Schwab SJ, Teehan BP, Toto R. Effect of dialysis dose and membrane flux in maintenance hemodialysis. N Engl J Med. 2002; 347:2010-2019.
23. Arora P, Kausz AT, Obrador GT, Ruthazer R, Khan S, Jenuleson CS, Meyer KB, Pereira BJ. Hospital utilization among chronic dialysis patients. J Am Soc Nephrol. 2000; 11:740-746.
24. Xia H, Ebben J, Ma JZ, Collins AJ. Hematocrit levels and hospitalization risks in hemodialysis patients. J Am Soc Nephrol. 1999; 10:1309-1316.
25. Kausz AT, Obrador GT, Arora P, Ruthazer R, Levey AS, Pereira BJ. Late initiation of dialysis among women and ethnic minorities in the United States. J Am Soc Nephrol. 2000; 11:2351-2357.
26. Obrador GT, Pereira BJ. Early referral to the nephrologist and timely initiation of renal replacement therapy: A paradigm shift in the management of patients with chronic renal failure. Am J Kidney Dis. 1998; 31:398-417.
27. Kinchen KS, Sadler J, Fink N, Brookmeyer R, Klag MJ, Levey AS, Powe NR. The timing of specialist evaluation in chronic kidney disease and mortality. Ann Intern Med. 2002; 137:479-486.
28. Department of Health and Human Services, Health Care Financing Administration Office of Clinical Standards and Quality Health Care Financing Administration. 1999 Annual Report, End Stage Renal Disease Clinical Performance Measures Project, 1999. Baltimore, MD.
29. McClellan WM, Hodgin E, Pastan S, McAdams L, Soucie M. A randomized evaluation of two health care quality improvement program (HCQIP) interventions to improve the adequacy of hemodialysis care of ESRD patients: Feedback alone versus intensive intervention. J Am Soc Nephrol. 2004; 15:754-760.
30. Sehgal AR. Impact of quality improvement efforts on race and sex disparities in hemodialysis. JAMA. 2003; 289:996-1000.
31. Frankenfield DL, Roman SH, Rocco MV, Bedinger MR, McClellan WM. Disparity in outcomes for adult native American hemodialysis patients? Findings from the ESRD clinical performance measures project, 1996 to 1999. Kidney Int. 2004; 65:1426-1434.
32. The morbidity, mortality and prescription of dialysis symposium. Proceedings, Dallas, TX, September 15-17, 1989. Am J Kidney Dis. 1990; 15:375-515.
33. Fink JC, Zhan M, Blahut SA, Soucie M, McClellan WM. Measuring the efficacy of a quality improvement program in dialysis adequacy with changes in center effects. J Am Soc Nephrol. 2002; 13:2338-2344.
34. Leggat JE Jr, Orzol SM, Hulbert-Shearon TE, Golper TA, Jones CA, Held PJ, Port FK. Noncompliance in hemodialysis: Predictors and survival analysis. Am J Kidney Dis. 1998; 32:139-145.
35. Collins AJ, Li S, St Peter W, Ebben J, Roberts T, Ma JZ, Manning W. Death, hospitalization, and economic associations among incident hemodialysis patients with hematocrit values of 36 to 39%. J Am Soc Nephrol. 2001; 12:2465-2473.
36. London R, Solis A, Goldberg GA, Wade S, Ryu S. Health care resource utilization and the impact of anemia management in patients with chronic kidney disease. Am J Kidney Dis. 2002; 40:539-548.
37. Ofsthun N, Labrecque J, Lacson E, Keen M, Lazarus JM. The effects of higher hemoglobin levels on mortality and hospitalization in hemodialysis patients. Kidney Int. 2003; 63:1908-1914.
38. Avorn J, Winkelmayer WC, Bohn RL, Levin R, Glynn RJ, Levy E, Owen W Jr. Delayed nephrologist referral and inadequate vascular access in patients with advanced chronic kidney failure. J Clin Epidemiol. 2002; 55:711-716.
39. Owen WF Jr. Patterns of care for patients with chronic kidney disease in the United States: Dying for improvement. J Am Soc Nephrol. 2003; 14:S76-S80.
40. Sands JJ, Perry MA. Improving vascular access outcomes: A systems approach to eliminating structural barriers. Blood Purif. 2003; 21:111-117.
41. Sands JJ, Ferrell LM, Perry MA. Systemic barriers to improving vascular access outcomes. Adv Ren Replace Ther. 2002; 9:109-115.
42. Besarab A, Sullivan KL, Ross RP, Moritz MJ. Utility of intra-access pressure monitoring in detecting and correcting venous outlet stenoses prior to thrombosis. Kidney Int. 1995; 47:1364-1373.
43. Schwab SJ, Oliver MJ, Suhocki P, McCann R. Hemodialysis arteriovenous access: Detection of stenosis and response to treatment by vascular access blood flow. Kidney Int. 2001; 59:358-362.
44. Schwab SJ. Improving access patency: Pre-end-stage renal disease strategies. J Am Soc Nephrol. 1998; 9:S124-S129.
45. Moist LM, Churchill DN, House AA, Millward SF, Elliott JE, Kribs SW, DeYoung WJ, Blythe L, Stitt LW, Lindsay RM. Regular monitoring of access flow compared with monitoring of venous pressure fails to improve graft survival. J Am Soc Nephrol. 2003; 14:2645-2653.
46. Ram SJ, Work J, Caldito GC, Eason JM, Pervez A, Paulson WD. A randomized controlled trial of blood flow and stenosis surveillance of hemodialysis grafts. Kidney Int. 2003; 64:272-280.
47. Kliger AS. Serum albumin measurement in dialysis patients: Should it be a measure of clinical performance? J Ren Nutr. 2002; 12:145-147.
48. Jones CH, Newstead CG, Will EJ, Smye SW, Davison AM. Assessment of nutritional status in CAPD patients: Serum albumin is not a useful measure. Nephrol Dial Transplant. 1997; 12:1406-1413.
49. Jones CH, Newstead CG, Wills EJ, Davison AM. Serum albumin and survival in CAPD patients: The implications of concentration trends over time. Nephrol Dial Transplant. 1997; 12:554-558.
50. Jones CH, Smye SW, Newstead CG, Will EJ, Davison AM. Extracellular fluid volume determined by bioelectric impedance and serum albumin in CAPD patients. Nephrol Dial Transplant. 1998; 13:393-397.
51. Ayus JC, Sheikh-Hamad D. Silent infection in clotted hemodialysis access grafts. J Am Soc Nephrol. 1998; 9: 1314-1317.
52. Leon JB, Majerle AD, Soinski JA, Kushner I, Ohri-Vachaspati P, Sehgal AR. Can a nutrition intervention improve albumin levels among hemodialysis patients? A pilot study. J Ren Nutr. 2001; 11:9-15.
53. Longenecker JC, Coresh J, Klag MJ, Levey AS, Martin AA, Fink NE, Powe NR. Validation of comorbid conditions on the end-stage renal disease medical evidence report: The CHOICE study. Choices for healthy outcomes in caring for ESRD. J Am Soc Nephrol. 2000; 11:520-529.
54. Fink JC, Blahut SA, Briglia AE, Gardner JF, Light PD. Effect of center- versus patient-specific factors on variations in dialysis adequacy. J Am Soc Nephrol. 2001; 12: 164-169.